QALYs in Health Resource Usage Decisions (Reply)

In this reply, the authors defend the quality-adjusted life-year (QALY) as a rigorous tool for health resource allocation while acknowledging it should be one component of decision-making, and argue that rarity alone should not warrant higher drug prices when public incentives already subsidize rare disease drug development.